NCT02447276已完成2 期
A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 421
- 主要终点
- The primary endpoint in the study is the change from baseline to week 16 in the Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain subscale score.
研究概览
简要总结
The primary objective of this study is to evaluate the effectiveness of REGN475 compared to placebo in participants with pain due to osteoarthritis (OA) of the knee or hip and a history of inadequate joint pain relief or intolerance to current analgesic therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Body mass index ≤39
- •Clinical diagnosis of OA of the knee or hip
- •History of inadequate pain relief or intolerance to analgesics used for OA
- •Moderate to severe pain in the index joint
- •History of regular use of analgesic medications for OA pain
- •Willing to discontinue current non-steroidal anti-inflammatory drug (NSAID) and opioid pain medications
排除标准
- •Other diseases that may involve index knee or hip, including inflammatory joint diseases, crystalline disease (gout or pseudogout), endocrinopathies, metabolic joint disease, lupus erythematosus, rheumatoid arthritis, joint infections, neuropathic disorders, avascular necrosis, Paget's disease, renal osteodystrophy or tumors
- •History of osteonecrosis, destructive arthropathy (RPOA), hip dislocation, pathologic fractures, neuropathic joint arthropathy, knee dislocation or hip dislocation
- •Trauma to the index joint in the 30 days before screening
- •Active fibromyalgia, regional pain caused by lumbar or cervical compression with radiculopathy or other moderate to severe pain that may confound assessments or self-evaluation of the pain associated with OA
- •Prior to the start of the study has received a recommendation for, or is scheduled for joint replacement surgery to be performed during the study period
- •Presence of subchondral insufficiency fracture on screening films or MRI
- •Received an intra-articular injection of hyaluronic acid in the affected index joint within 90 days prior to the screening visit
- •Systemic (ie, oral or intramuscular) corticosteroids within 30 days prior to the screening visit. Intra-articular corticosteroids in the index joint within 12 weeks of the screening visit, or to any other joint within 30 days prior to the screening visit.
- •History of autonomic neuropathy, diabetic neuropathy, or presence of clinically relevant peripheral neuropathy at the time of screening
- •Women of childbearing potential who have a positive pregnancy test result, or who do not have their pregnancy test results at baseline
- •Pregnant or breastfeeding women
研究组 & 干预措施
Group A
Experimental
Group A will receive REGN475 dosing regimen 1
干预措施: REGN475 (Drug)
Group B
Experimental
Group B will receive REGN475 dosing regimen 2
干预措施: REGN475 (Drug)
Group C
Experimental
Group C will receive REGN475 dosing regimen 3
干预措施: REGN475 (Drug)
Group D
Experimental
Group D will receive REGN475 dosing regimen 4
干预措施: REGN475 (Drug)
Group E
Experimental
Group E will receive matching placebo
干预措施: Placebo (Drug)
结局指标
主要结局
The primary endpoint in the study is the change from baseline to week 16 in the Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain subscale score.
时间窗: Baseline to week 16
次要结局
- Change from baseline to week 16 in the WOMAC physical function subscale score(Baseline to week 16)
- Change from baseline to week 16 in the Patient Global Assessment score(Baseline to week 16)
- Incidence of anti-REGN475 antibody development(Baseline to week 36 (end of study))
- Incidence of treatment-emergent adverse events (TEAEs)(Baseline to week 36 (end of study))
研究者
相似试验
终止
2 期
A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the KneeOsteoarthritis of the KneePainNCT03956550Regeneron Pharmaceuticals259
撤回
2 期
Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal InjuryThermal Injury PainNCT01053702Regeneron Pharmaceuticals
已完成
1 期
Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult MenHealthy VolunteersNCT02943239Regeneron Pharmaceuticals82
终止
2 期
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic DermatitisAtopic DermatitisNCT03736967Regeneron Pharmaceuticals206
终止
3 期
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a CatAllergic Rhinitis Due to Cat AllergyNCT04981717Regeneron Pharmaceuticals446